Beryl Drugs Ltd.
24.89-0.1 (-0.44%)
22 Oct, 12:00 AM
Stock Scores
Quality Score
Score not available
Value Score
Score not available
Price Momentum Score
Score not available
QVM Score
Score not available
Key Metrics
Stock Analysis
Fundamental analysis overview of Beryl Drugs Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Stock is reasonably valued and PE TTM is at a discount to industry median
PE TTM of 20.21 indicates that the stock is reasonably valued on a standalone basis. Discount to industry median P/E is decent at -34.36%
What is P/E Ratio?
Median: 30.79
Value 20.21
-0.85654.83
Negative
Low dividend yield
The company has a low dividend yield of 0.0%
What is Dividend yield?
Neutral
Not enough talking points with neutral stance
Financial Snapshot
See detailed analysisMulti-year trends for Beryl Drugs Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Beryl Drugs Ltd. shares as reported to NSE and BSE.
| Name | Month | Transaction | Holding % pre transaction | Average price | Qty. | Transaction value |
|---|---|---|---|---|---|---|
SUDHIR SETHI Promoter and Director | August-2026 | Market Purchase (Acquisition) 18th Aug 2026 | 10.08 % | ₹ 23.00 | 3.00 k | ₹ 69.00 k |
SUDHIR SETHI Promoter & Director | June-2026 | Market Purchase (Acquisition) 9th Jun 2026 | 9.75 % | ₹ 24.00 | 4.68 k | ₹ 1.12 lac |
SUDHIR SETHI Promoter & Director | June-2026 | Market Purchase (Acquisition) 7th Jun 2026 | 9.72 % | ₹ 21.92 | 1.99 k | ₹ 43.66 k |
SUDHIR SETHI Promoter & Director | March-2026 | Market Purchase (Acquisition) 25th Mar 2026 | 9.58 % | ₹ 20.99 | 7.50 k | ₹ 1.57 lac |
SUDHIR SETHI Promoter & Director | March-2026 | Market Purchase (Acquisition) 24th Mar 2026 | 9.44 % | ₹ 20.75 | 7.50 k | ₹ 1.56 lac |
SUDHIR SETHI Promoter & Director | March-2026 | Market Purchase (Acquisition) 21st Mar 2026 | 9.42 % | ₹ 20.80 | 800.00 | ₹ 16.64 k |
SUDHIR SETHI Promoter & Director | March-2026 | Market Purchase (Acquisition) 17th Mar 2026 | 9.33 % | ₹ 20.20 | 5.00 k | ₹ 1.01 lac |
SUDHIR SETHI Promoter & Director | March-2026 | Market Purchase (Acquisition) 14th Mar 2026 | 9.27 % | ₹ 20.23 | 3.04 k | ₹ 61.50 k |
SUDHIR SETHI Promoter & Director | March-2026 | Market Purchase (Acquisition) 13th Mar 2026 | 8.98 % | ₹ 20.48 | 15.00 k | ₹ 3.07 lac |
SUDHIR SETHI Promoter & Director | March-2026 | Market Purchase (Acquisition) 12th Mar 2026 | 8.88 % | ₹ 20.88 | 4.85 k | ₹ 1.01 lac |
No corporate action data available.
Company Profile
Overview of Beryl Drugs Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Beryl Drugs Limited is an India-based pharmaceutical manufacturing company which is principally engaged in the manufacturing of bulk drugs. The Company operates in Pharmaceutical Industry segment. In response to product requirements, it provides a variety of manufacturing options, such as small volu...
Key personnel
Mr. Ashish Baraskar
Chief Financial Officer
Kamlesh Gupta
Compliance Officer, Company Secretary
Mr. Sudhir SethiD
Non-Executive Chairman of the Board
Mr. Sanjay SethiD
Managing Director, Executive Director
Mr. Shailendra PathakD
Whole Time Director
Mr. Abhinav NaikD
Independent Non-Executive Director
Mrs. Shreya SarafD
Independent Non-Executive Director
Neha SardaD
Non-Executive Independent Director
Incorporated on
24 Aug 1993
Last Annual
31 Mar 2026
Last Interim
30 Jun 2026
No. of Employees
-
IPO date
16 Jun 1994
Free Float
30,18,767
Website
Phone no.
+917312517677
Address
133 KANCHAN BAGH, , 452001, India
Frequently Asked Questions
What is the current share price of Beryl Drugs Ltd.?
The current share price of Beryl Drugs Ltd. is ₹ 24.89 as of 22 Oct 2026.
What is the market capitalisation of Beryl Drugs Ltd.?
The market capitalisation of Beryl Drugs Ltd. stands at ₹ 12.62 Cr.
What is the PE ratio of Beryl Drugs Ltd.?
The Price-to-Earnings (PE) ratio of Beryl Drugs Ltd. is 20.21 as of the latest trailing twelve months data.
What is the ROE and ROCE of Beryl Drugs Ltd.?
Beryl Drugs Ltd. has a Return on Equity (ROE) of 4.38% and a Return on Capital Employed (ROCE) of 3.41% as per the latest financial reports.
What is the 52-week high and low of Beryl Drugs Ltd.?
The 52-week high of Beryl Drugs Ltd. is - and the 52-week low is -.
What is the dividend yield of Beryl Drugs Ltd.?
The dividend yield of Beryl Drugs Ltd. is 0.00% based on the current market price.
What is the FII and DII holding in Beryl Drugs Ltd.?
Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 69.49% of Beryl Drugs Ltd. shares.
What sector does Beryl Drugs Ltd. belong to?
Beryl Drugs Ltd. operates in the Healthcare sector.
What is the beta of Beryl Drugs Ltd.?
The beta of Beryl Drugs Ltd. is 0.76, indicating its price volatility relative to the broader market. Over the past 1 year, Beryl Drugs Ltd. has delivered an absolute return of 9.41%.
What is the RSI of Beryl Drugs Ltd.?
The 14-day Relative Strength Index (RSI) of Beryl Drugs Ltd. is 52.19, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.